Home » Healthcare » Automated Insulin Delivery System Market

Automated Insulin Delivery System Market By Product Type (Hybrid Closed-Loop Systems, Fully Automated Closed-Loop Systems, Predictive Low Glucose Suspend System); By Component (Insulin Pumps, Continuous Glucose Monitors (CGM), Control Software and Apps); By Diabetes Type (Type 1 Diabetes, Type 2 Diabetes); By End User (Hospitals and Clinics, Homecare Patients, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

Market Overview

The Automated Insulin Delivery System Market size was valued at USD 2,685.93 million in 2018 to USD 4,403.17 million in 2024 and is anticipated to reach USD 8,728.27 million by 2032, at a CAGR of 8.32 % during the forecast period.

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Automated Insulin Delivery System Market Size 2024	USD 4,403.17 million
Automated Insulin Delivery System Market, CAGR	8.32%
Automated Insulin Delivery System Market Size 2032	USD 8,728.27 million

The Automated Insulin Delivery System Market is driven by the rising global prevalence of diabetes, increasing demand for personalized and continuous glucose management, and growing adoption of wearable medical technologies. Advancements in closed-loop systems, integration with continuous glucose monitors (CGMs), and real-time data analytics enhance system precision and patient outcomes. Key trends include the development of hybrid and fully automated insulin delivery systems, AI-enabled dosing algorithms, and smartphone integration for remote monitoring. Market players are focusing on compact, user-friendly designs and interoperability, while regulatory support and reimbursement policies further accelerate market adoption across developed and emerging regions.

The Automated Insulin Delivery System Market spans key regions including North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America leads in adoption, followed by strong growth in Europe and rapid expansion in Asia Pacific. Latin America, the Middle East, and Africa show steady potential driven by improving healthcare access. Key players operating globally include Medtronic, Insulet Corporation, Tandem Diabetes Care, Dexcom, Abbott, Roche Diabetes Care, Ypsomed AG, Bigfoot Biomedical, Diabeloop, Beta Bionics, EOFlow, and Senseonics Holdings, strengthening competition and innovation across all regions.

Market Insights

The Automated Insulin Delivery System Market reached USD 4,403.17 million in 2024 and is projected to hit USD 8,728.27 million by 2032, growing at a CAGR of 8.32%.
Rising global diabetes prevalence, especially type 1 diabetes, continues to drive demand for precise, continuous insulin management solutions.
Technological advancements such as AI-based dosing, improved CGMs, and smartphone connectivity enhance usability and patient outcomes.
High device cost and limited reimbursement access, especially in emerging regions, remain key barriers to broader market adoption.
North America leads the market with USD 1,901.31 million in 2024, driven by strong infrastructure, favorable policies, and early adoption.
Asia Pacific is the fastest-growing region with a CAGR of 10.1%, supported by rising healthcare investments and government-backed diabetes programs.
Key players including Medtronic, Insulet, Tandem, Dexcom, Abbott, and Roche are focusing on innovation, partnerships, and regional expansion to strengthen their global footprint.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Drivers

Rising Diabetes Prevalence and Demand for Improved Glycemic Control

The Automated Insulin Delivery System Market is primarily driven by the global surge in diabetes cases, particularly type 1 diabetes, where precise insulin dosing is critical. Patients and healthcare providers seek advanced systems that ensure tighter glucose control and reduce long-term complications. It addresses these needs through continuous glucose monitoring paired with automated insulin adjustments. Rising awareness of the benefits of closed-loop systems increases demand. Growing healthcare expenditure further supports adoption. The need for reducing hypoglycemia risk strengthens market growth.

For instance, in 2023, Medtronic’s MiniMed 780G system was approved by the FDA, offering real-time adjustments every 5 minutes and delivering auto-corrections to help users maintain target glucose levels, especially overnight.

Technological Advancements in Sensor and Algorithm Integration

Innovations in continuous glucose monitoring and insulin pump technologies significantly contribute to the Automated Insulin Delivery System Market. It benefits from AI-driven algorithms that enable predictive insulin dosing and adaptive learning based on user behavior. Enhanced sensor accuracy, real-time alerts, and cloud-based data sharing improve decision-making. Wireless connectivity and smartphone integration improve usability. Market players invest in research to deliver compact, intelligent systems. These technological improvements expand appeal among younger, tech-savvy diabetic populations.

For instance, Tandem Diabetes Care’s t:slim X2 insulin pump with Control-IQ technology integrates with CGMs and uses predictive modeling to reduce both hyperglycemia and hypoglycemia events.

Growing Preference for Wearable and User-Friendly Devices

User comfort and device simplicity drive adoption of automated insulin delivery systems. The Automated Insulin Delivery System Market is responding with wearable solutions that blend into daily routines. Lightweight, discreet designs with intuitive interfaces appeal to both adult and pediatric users. It offers freedom from manual insulin injections and reduces patient burden. Healthcare providers favor such systems for their ease of training and compliance. This shift toward patient-centric design broadens the user base significantly.

Supportive Regulatory Framework and Reimbursement Policies

Supportive regulatory pathways and favorable reimbursement structures boost the Automated Insulin Delivery System Market. It receives increasing attention from health agencies recognizing its role in reducing diabetes-related complications. Regulatory bodies streamline approval processes for integrated technologies. Public and private insurers now cover many devices, encouraging early adoption. Governments and NGOs promote awareness and funding for diabetes management programs. These factors improve accessibility, especially in developed economies. This regulatory support accelerates innovation and commercial success.

Market Trends

Integration of Artificial Intelligence and Adaptive Algorithms Enhances Personalization

The Automated Insulin Delivery System Market is experiencing a shift toward AI-powered systems that personalize insulin dosing based on real-time data. Advanced algorithms analyze glucose trends, meal patterns, and activity levels to make precise dosing decisions. These systems reduce hypoglycemia risk and improve time-in-range outcomes. AI integration supports predictive adjustments, helping patients maintain stable glucose levels. It enables smarter, patient-specific insulin delivery with minimal manual input. Continuous algorithm refinement improves reliability and user confidence.

For instance, the iLet® Bionic Pancreas from Beta Bionics uses machine learning to automate insulin delivery with no need for users to input carb counts, making personalized dosing more seamless and accessible for people with type 1 diabetes.

Smartphone Connectivity and Remote Monitoring Drive User Engagement

Smartphone integration has emerged as a core trend in the Automated Insulin Delivery System Market, offering real-time tracking and data visualization. Patients and caregivers access glucose and insulin data remotely through apps, improving engagement and adherence. It enables physicians to monitor trends and adjust treatment plans promptly. Enhanced user interfaces and alerts support informed decision-making. Remote monitoring increases system value, particularly for pediatric and elderly users. Connectivity transforms diabetes management into a more responsive and transparent process.

Hybrid Closed-Loop Systems Evolve Toward Fully Automated Solutions

The market is moving from hybrid closed-loop systems to fully automated insulin delivery, aiming for complete hands-off glucose control. Hybrid systems require periodic manual input, while newer models automate most dosing decisions. It reflects increasing demand for convenience and precision. Major players are investing in R&D to remove the need for carbohydrate counting or user overrides. Fully automated systems offer superior glycemic outcomes with minimal user burden. This trend positions them as the future standard in diabetes care.

For instance, Beta Bionics’ iLet Bionic Pancreas, FDA-cleared in 2023, adjusts insulin dosing automatically based solely on the user’s body weight, requiring no carb-counting or manual adjustments from users.

Emphasis on Compact Design and Wearability Expands Patient Adoption

Wearable comfort and discreet design play a crucial role in accelerating demand within the Automated Insulin Delivery System Market. Compact, tubeless systems that adhere to the body offer greater mobility and freedom. It appeals to active users and pediatric patients who prioritize convenience. Manufacturers focus on lightweight, waterproof, and skin-friendly materials to enhance daily usability. Ease of use supports consistent wear and treatment adherence. These advancements make automated delivery systems more approachable for a broader population.

Market Challenges Analysis

High Cost of Devices and Limited Reimbursement Hinder Widespread Adoption

The Automated Insulin Delivery System Market faces significant barriers due to the high upfront cost of devices and associated components. Many patients, particularly in low- and middle-income regions, cannot afford these systems without insurance support. Limited or inconsistent reimbursement policies restrict access even in developed countries. Insurers often hesitate to cover advanced systems due to unclear long-term cost-benefit data. This limits market penetration and creates inequality in diabetes management. It remains a challenge for manufacturers to balance innovation with affordability. Expanding access depends on stronger payer-provider collaborations and value-based pricing models.

Technical Limitations and Regulatory Complexity Delay Market Expansion

The Automated Insulin Delivery System Market also struggles with technical and regulatory challenges that delay product rollout and adoption. Sensor inaccuracies, delayed insulin absorption, and software glitches compromise system reliability. Regulatory agencies enforce strict safety standards, requiring extensive clinical validation and slowing approval timelines. It faces hurdles in ensuring real-time data accuracy, cybersecurity, and interoperability across platforms. Device recalls and data privacy concerns also affect user trust. Navigating these technical and compliance issues increases development costs and extends time-to-market. Industry players must address these concerns to scale adoption effectively.

Market Opportunities

Expansion into Emerging Markets with Growing Diabetic Population Creates New Demand

The Automated Insulin Delivery System Market holds strong growth potential in emerging economies where diabetes prevalence continues to rise. Countries across Asia-Pacific, Latin America, and the Middle East are witnessing increased diagnosis rates and a growing need for advanced diabetic care. Rising healthcare investments and improved infrastructure support device adoption. Governments and NGOs are launching awareness campaigns and funding programs to expand access. It can leverage this demand by introducing cost-effective models and building local distribution networks. Collaborating with regional healthcare providers and policymakers can accelerate product acceptance. These markets offer untapped growth opportunities for scalable and adaptable solutions.

Integration with Digital Health Platforms and AI Enhances System Value

The Automated Insulin Delivery System Market benefits from the growing shift toward connected healthcare ecosystems. Integration with mobile apps, wearable devices, and AI-driven analytics enables personalized, data-backed insulin management. It allows real-time monitoring, remote physician access, and improved patient adherence. Expanding partnerships with digital health startups and telehealth platforms enhances ecosystem value. This creates a pathway for insurers to support device use through outcome-based models. It also opens doors for continuous upgrades through software enhancements without requiring hardware replacements. These innovations position the market to evolve beyond traditional diabetes management.

Market Segmentation Analysis:

By Product Type

The Automated Insulin Delivery System Market includes hybrid closed-loop systems, fully automated closed-loop systems, and predictive low glucose suspend (PLGS) systems. Hybrid systems dominate due to their proven performance and user familiarity. Fully automated systems are gaining momentum with increased preference for hands-free operation and improved glycemic control. PLGS systems offer targeted intervention to prevent hypoglycemia, making them valuable for nocturnal use and pediatric patients. Each product type serves distinct clinical needs, allowing manufacturers to address varied diabetic populations. It continues to evolve as innovation pushes systems toward greater automation and personalized dosing.

For instance, the Omnipod 5 system, notable as the first tubeless hybrid closed-loop pump, combines with Dexcom G6 CGM to deliver automated basal insulin dosing but still relies on users for bolus insulin at meals, offering freedom from tubing while managing glucose effectively.

By Component

The market comprises insulin pumps, continuous glucose monitors (CGMs), and control software and apps. CGMs hold a large share due to their critical role in real-time glucose tracking. Insulin pumps are central to the delivery mechanism and are being refined for accuracy and portability. Control software and apps enhance system functionality by integrating data analytics, remote access, and customization features. The Automated Insulin Delivery System Market benefits from the seamless integration of these components. It supports patient adherence and clinical oversight through connected and intelligent device ecosystems.

For instance, Roche unveiled its Accu-Chek SmartGuide CGM with predictive AI technology that forecasts glucose trends up to two hours ahead, helping users proactively manage glucose levels and avoid hypoglycemia through advanced pattern recognition and digital tools.

By Diabetes Type

Type 1 diabetes accounts for the largest share in the Automated Insulin Delivery System Market due to the intensive insulin management it requires. These systems offer significant benefits in reducing glucose variability and minimizing hypoglycemia risk. Type 2 diabetes represents a growing opportunity as insulin-dependent patients seek alternatives to manual injection regimens. It supports a shift toward technology-driven chronic disease management. Manufacturers are expanding indications to cater to this broader diabetic group with scalable system options.

Segments:

Based on Product Type

Hybrid Closed-Loop Systems
Fully Automated Closed-Loop Systems
Predictive Low Glucose Suspend System

Based on Component

Insulin Pumps
Continuous Glucose Monitors (CGM)
Control Software and Apps

Based on Diabetes Type

Type 1 Diabetes
Type 2 Diabetes

Based on End User

Hospitals and Clinics
Homecare Patients
Others

Based on Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

Regional Analysis

North America

The North America Automated Insulin Delivery System Market size was valued at USD 1,171.98 million in 2018 to USD 1,901.31 million in 2024 and is anticipated to reach USD 3,779.39 million by 2032, at a CAGR of 8.4% during the forecast period. North America holds the largest market share, driven by high diabetes prevalence, advanced healthcare infrastructure, and strong adoption of medical technology. The U.S. leads regional growth due to favorable reimbursement policies and widespread use of insulin pumps and CGMs. Key players actively launch new automated systems and expand clinical trials. It benefits from government support for digital health and chronic disease management. The presence of major manufacturers and early technology adopters strengthens North America’s dominance in the global landscape.

Europe

The Europe Automated Insulin Delivery System Market size was valued at USD 792.97 million in 2018 to USD 1,254.91 million in 2024 and is anticipated to reach USD 2,347.93 million by 2032, at a CAGR of 7.5% during the forecast period. Europe holds the second-largest market share, supported by strong public healthcare systems and increasing focus on diabetes control. Countries like Germany, France, and the UK lead in device adoption and reimbursement access. It experiences growth through clinical guidelines favoring automated insulin delivery systems. Regulatory alignment and CE approvals facilitate swift market entry for new devices. Growing demand for non-invasive glucose monitoring further boosts regional expansion.

Asia Pacific

The Asia Pacific Automated Insulin Delivery System Market size was valued at USD 473.64 million in 2018 to USD 847.50 million in 2024 and is anticipated to reach USD 1,921.22 million by 2032, at a CAGR of 10.1% during the forecast period. Asia Pacific is the fastest-growing region due to rising diabetes cases, urbanization, and expanding access to advanced medical technologies. China, India, Japan, and South Korea lead demand with increasing healthcare investments and awareness. It benefits from improving affordability and domestic manufacturing of CGMs and insulin pumps. Government-backed diabetes programs and digital health adoption support long-term growth. Local partnerships and distribution networks help market penetration across rural and semi-urban areas.

Latin America

The Latin America Automated Insulin Delivery System Market size was valued at USD 129.25 million in 2018 to USD 209.29 million in 2024 and is anticipated to reach USD 368.10 million by 2032, at a CAGR of 6.7% during the forecast period. Latin America shows steady growth driven by increasing diabetes diagnosis and a shift toward modern diabetes management. Brazil and Mexico are the primary contributors, supported by expanding private healthcare infrastructure. It faces cost-related adoption barriers but gains momentum through NGO-led awareness and pilot programs. Regional demand grows for affordable and easy-to-use insulin delivery devices. Innovation in mobile-linked systems appeals to tech-savvy populations in urban areas.

Middle East

The Middle East Automated Insulin Delivery System Market size was valued at USD 75.82 million in 2018 to USD 113.71 million in 2024 and is anticipated to reach USD 190.48 million by 2032, at a CAGR of 6.0% during the forecast period. The Middle East market benefits from rising diabetes incidence, government health initiatives, and increasing insurance coverage. GCC countries lead regional demand with strong healthcare investments and early device adoption. It sees growing interest in wearable solutions and mobile-integrated platforms. Multinational companies expand presence through local partnerships and clinical collaborations. Market growth relies on balancing affordability with high-end features for long-term management.

Africa

The Africa Automated Insulin Delivery System Market size was valued at USD 42.28 million in 2018 to USD 76.44 million in 2024 and is anticipated to reach USD 121.16 million by 2032, at a CAGR of 5.3% during the forecast period. Africa presents untapped potential in the automated insulin delivery space, driven by rising diabetes awareness and healthcare development. South Africa and Egypt are key growth hubs with improving infrastructure and medical device access. It faces challenges in affordability, diagnosis rates, and specialist availability. Market penetration depends on NGO support, government health programs, and mobile health platforms. Long-term growth will rely on low-cost innovations and training of healthcare providers.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

Diabeloop
Dexcom Inc.
Ascensia Diabetes Care
Medtronic
Senseonics Holdings, Inc.
EOFlow Co., Ltd.
Bigfoot Biomedical
Tandem Diabetes Care
Roche Diabetes Care
Sooil Development Co., Ltd.
Ypsomed AG
Cellnovo Group SA (Acquired by Tandem)
Abbott Laboratories
Insulet Corporation
Beta Bionics

Competitive Analysis

The Automated Insulin Delivery System Market features intense competition led by established medical device companies and innovative startups. Major players such as Medtronic, Tandem Diabetes Care, and Insulet Corporation dominate through extensive product portfolios and strong distribution networks. Companies like Dexcom and Abbott contribute with advanced CGM technologies that integrate seamlessly with insulin pumps. Emerging players, including Beta Bionics, Bigfoot Biomedical, and Diabeloop, focus on algorithm-driven automation and closed-loop innovations. It witnesses frequent product launches, strategic collaborations, and clinical trials to gain regulatory approvals and market share. Players invest in AI-based solutions, compact hardware, and user-friendly platforms to differentiate offerings. Market competitiveness depends on pricing, integration capabilities, and digital support features.

Recent Developments

In April 2025, Medtronic submitted FDA 510(k) applications to enable its MiniMed 780G insulin pump and SmartGuard algorithm to operate with Abbott’s CGM platform, advancing their interoperability partnership.
In March 2025, Tandem Diabetes Care launched the Control-IQ+ system, expanding its automated insulin delivery technology to support individuals as young as two years old with type 1 diabetes.
On April 29, 2025, Sequel Med Tech entered into a collaboration with Senseonics to co-develop an AID system that incorporates a one-year implantable CGM, marking a significant innovation in long-term monitoring.
On June 23, 2025, Tandem Diabetes Care partnered with Abbott to integrate Abbott’s dual glucose-ketone sensor into Tandem’s AID platform, enhancing metabolic monitoring capabilities.

Market Concentration & Characteristics

The Automated Insulin Delivery System Market is moderately concentrated, with a few dominant players holding significant market share due to established brand presence, advanced technologies, and extensive distribution networks. Companies like Medtronic, Insulet Corporation, Tandem Diabetes Care, and Dexcom lead through continuous innovation and integration of CGMs and insulin pumps. It features high entry barriers due to stringent regulatory requirements, complex product development, and the need for clinical validation. The market emphasizes reliability, real-time data integration, and user-centric design. Growth depends on product differentiation, AI-enabled automation, and interoperability across platforms. Smaller players and startups focus on specialized algorithms and regional market customization to gain traction. It also reflects high R&D intensity and strategic partnerships to enhance market presence and meet evolving patient needs. Market dynamics favor companies capable of balancing innovation, affordability, and scalability in response to increasing global diabetes burden.

Report Coverage

The research report offers an in-depth analysis based on Product Type, Component, Diabetes Type, End-User and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

Demand for fully automated closed-loop systems will grow due to rising preference for hands-free insulin management.
Integration of AI and machine learning will enhance dosing precision and personalization.
Smartphone apps and cloud platforms will support remote monitoring and patient engagement.
Compact, wearable, and discreet devices will attract younger and active diabetic users.
Regional expansion in Asia Pacific, Latin America, and the Middle East will drive new revenue streams.
Partnerships between tech firms and healthcare providers will accelerate innovation and adoption.
Regulatory support and favorable reimbursement policies will improve market accessibility.
Companies will invest in interoperable platforms to integrate pumps, CGMs, and software seamlessly.
Low-cost models tailored for emerging markets will increase adoption in underserved regions.
Growing awareness and education around diabetes technology will support long-term market growth.

CHAPTER NO. 1: GENESIS OF THE MARKET

1.1 Market Prelude – Introduction & Scope

1.2 The Big Picture – Objectives & Vision

1.3 Strategic Edge – Unique Value Proposition

1.4 Stakeholder Compass – Key Beneficiaries

CHAPTER NO. 2: EXECUTIVE LENS

2.1 Pulse of the Industry – Market Snapshot

2.2 Growth Arc – Revenue Projections (USD Million)

2.3. Premium Insights – Based on Primary Interviews

CHAPTER NO. 3: AUTOMATED INSULIN DELIVERY SYSTEM MARKET FORCES & INDUSTRY PULSE

3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown

3.6 Price Trend Analysis

3.6.1 Regional Price Trend
3.6.2 Price Trend by Product

CHAPTER NO. 4: KEY INVESTMENT EPICENTER

4.1 Regional Goldmines – High-Growth Geographies

4.2 Product Frontiers – Lucrative Product Categories

4.3 Application Sweet Spots – Emerging Demand Segments

CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING

5.1 Momentum Metrics – Forecast & Growth Curves

5.2 Regional Revenue Footprint – Market Share Insights

5.3 Segmental Wealth Flow – Product Type & Diabetes Type Revenue

CHAPTER NO. 6: TRADE & COMMERCE ANALYSIS

6.1. Import Analysis by Region

6.1.1. Global Automated Insulin Delivery System Market Import Volume By Region

6.2. Export Analysis by Region

6.2.1. Global Automated Insulin Delivery System Market Export Volume By Region

CHAPTER NO. 7: COMPETITION ANALYSIS

7.1. Company Market Share Analysis

7.1.1. Global Automated Insulin Delivery System Market: Company Market Share

7.1. Global Automated Insulin Delivery System Market Company Volume Market Share

7.2. Global Automated Insulin Delivery System Market Company Revenue Market Share

7.3. Strategic Developments

7.3.1. Acquisitions & Mergers

7.3.2. New Product Type Launch

7.3.3. Regional Expansion

7.4. Competitive Dashboard

7.5. Company Assessment Metrics, 2024

CHAPTER NO. 8: AUTOMATED INSULIN DELIVERY SYSTEM MARKET – BY PRODUCT TYPE SEGMENT ANALYSIS

8.1. Automated Insulin Delivery System Market Overview by Product Type Segment

8.1.1. Automated Insulin Delivery System Market Volume Share By Product Type

8.1.2. Automated Insulin Delivery System Market Revenue Share By Product Type

8.2. Hybrid Closed-Loop Systems

8.3. Fully Automated Closed-Loop Systems

8.4. Predictive Low Glucose Suspend Systems

CHAPTER NO. 9: AUTOMATED INSULIN DELIVERY SYSTEM MARKET – BY COMPONENT SEGMENT ANALYSIS

9.1. Automated Insulin Delivery System Market Overview by Component Segment

9.1.1. Automated Insulin Delivery System Market Volume Share By Component

9.1.2. Automated Insulin Delivery System Market Revenue Share By Component

9.2. Insulin Pumps

9.3. Continuous Glucose Monitors (CGM)

9.4. Control Software and Apps

CHAPTER NO. 10: AUTOMATED INSULIN DELIVERY SYSTEM MARKET – BY DIABETES TYPE SEGMENT ANALYSIS

10.1. Automated Insulin Delivery System Market Overview by Diabetes Type Segment

10.1.1. Automated Insulin Delivery System Market Volume Share By Diabetes Type

10.1.2. Automated Insulin Delivery System Market Revenue Share By Diabetes Type

10.2. Type 1 Diabetes

10.3. Type 2 Diabetes

CHAPTER NO. 11: AUTOMATED INSULIN DELIVERY SYSTEM MARKET – BY END USER SEGMENT ANALYSIS

11.1. Automated Insulin Delivery System Market Overview by End User Segment

11.1.1. Automated Insulin Delivery System Market Volume Share By End User

11.1.2. Automated Insulin Delivery System Market Revenue Share By End User

11.2. Hospitals and Clinics

11.3. Homecare Patients

11.4. Others

CHAPTER NO. 12: AUTOMATED INSULIN DELIVERY SYSTEM MARKET – REGIONAL ANALYSIS

12.1. Automated Insulin Delivery System Market Overview by Region Segment

12.1.1. Global Automated Insulin Delivery System Market Volume Share By Region

12.1.2. Global Automated Insulin Delivery System Market Revenue Share By Region

12.1.3. Regions

12.1.4. Global Automated Insulin Delivery System Market Volume By Region

12.1.5. Global Automated Insulin Delivery System Market Revenue By Region

12.1.6. Product Type

12.1.7. Global Automated Insulin Delivery System Market Volume By Product Type

12.1.8. Global Automated Insulin Delivery System Market Revenue By Product Type

12.1.9. Component

12.1.10. Global Automated Insulin Delivery System Market Volume By Component

12.1.11. Global Automated Insulin Delivery System Market Revenue By Component

12.1.12. Diabetes Type

12.1.13. Global Automated Insulin Delivery System Market Volume By Diabetes Type

12.1.14. Global Automated Insulin Delivery System Market Revenue By Diabetes Type

12.1.12. End User

12.1.13. Global Automated Insulin Delivery System Market Volume By End User

12.1.14. Global Automated Insulin Delivery System Market Revenue By End User

CHAPTER NO. 13: NORTH AMERICA AUTOMATED INSULIN DELIVERY SYSTEM MARKET – COUNTRY ANALYSIS

13.1. North America Automated Insulin Delivery System Market Overview by Country Segment

13.1.1. North America Automated Insulin Delivery System Market Volume Share By Region

13.1.2. North America Automated Insulin Delivery System Market Revenue Share By Region

13.2. North America

13.2.1. North America Automated Insulin Delivery System Market Volume By Country

13.2.2. North America Automated Insulin Delivery System Market Revenue By Country

13.2.3. Product Type

13.2.4. North America Automated Insulin Delivery System Market Volume By Product Type

13.2.5. North America Automated Insulin Delivery System Market Revenue By Product Type

13.2.6. Component

13.2.7. North America Automated Insulin Delivery System Market Volume By Component

13.2.8. North America Automated Insulin Delivery System Market Revenue By Component

13.2.9. Diabetes Type

13.2.10. North America Automated Insulin Delivery System Market Volume By Diabetes Type

13.2.11. North America Automated Insulin Delivery System Market Revenue By Diabetes Type

13.2.12. End User

13.2.13. North America Automated Insulin Delivery System Market Volume By End User

13.2.14. North America Automated Insulin Delivery System Market Revenue By End User

13.3. U.S.

13.4. Canada

13.5. Mexico

CHAPTER NO. 14: EUROPE AUTOMATED INSULIN DELIVERY SYSTEM MARKET – COUNTRY ANALYSIS

14.1. Europe Automated Insulin Delivery System Market Overview by Country Segment

14.1.1. Europe Automated Insulin Delivery System Market Volume Share By Region

14.1.2. Europe Automated Insulin Delivery System Market Revenue Share By Region

14.2. Europe

14.2.1. Europe Automated Insulin Delivery System Market Volume By Country

14.2.2. Europe Automated Insulin Delivery System Market Revenue By Country

14.2.3. Product Type

14.2.4. Europe Automated Insulin Delivery System Market Volume By Product Type

14.2.5. Europe Automated Insulin Delivery System Market Revenue By Product Type

14.2.6. Component

14.2.7. Europe Automated Insulin Delivery System Market Volume By Component

14.2.8. Europe Automated Insulin Delivery System Market Revenue By Component

14.2.9. Diabetes Type

14.2.10. Europe Automated Insulin Delivery System Market Volume By Diabetes Type

14.2.11. Europe Automated Insulin Delivery System Market Revenue By Diabetes Type

14.2.12. End User

14.2.13. Europe Automated Insulin Delivery System Market Volume By End User

14.2.14. Europe Automated Insulin Delivery System Market Revenue By End User

14.3. UK

14.4. France

14.5. Germany

14.6. Italy

14.7. Spain

14.8. Russia

14.9. Rest of Europe

CHAPTER NO. 15: ASIA PACIFIC AUTOMATED INSULIN DELIVERY SYSTEM MARKET – COUNTRY ANALYSIS

15.1. Asia Pacific Automated Insulin Delivery System Market Overview by Country Segment

15.1.1. Asia Pacific Automated Insulin Delivery System Market Volume Share By Region

15.1.2. Asia Pacific Automated Insulin Delivery System Market Revenue Share By Region

15.2. Asia Pacific

15.2.1. Asia Pacific Automated Insulin Delivery System Market Volume By Country

15.2.2. Asia Pacific Automated Insulin Delivery System Market Revenue By Country

15.2.3. Product Type

15.2.4. Asia Pacific Automated Insulin Delivery System Market Volume By Product Type

15.2.5. Asia Pacific Automated Insulin Delivery System Market Revenue By Product Type

15.2.6. Component

15.2.7. Asia Pacific Automated Insulin Delivery System Market Volume By Component

15.2.8. Asia Pacific Automated Insulin Delivery System Market Revenue By Component

15.2.9. Diabetes Type

15.2.10. Asia Pacific Automated Insulin Delivery System Market Volume By Diabetes Type

15.2.11. Asia Pacific Automated Insulin Delivery System Market Revenue By Diabetes Type

15.2.12. End User

15.2.13. Asia Pacific Automated Insulin Delivery System Market Volume By End User

15.2.14. Asia Pacific Automated Insulin Delivery System Market Revenue By End User

15.3. China

15.4. Japan

15.5. South Korea

15.6. India

15.7. Australia

15.8. Southeast Asia

15.9. Rest of Asia Pacific

CHAPTER NO. 16: LATIN AMERICA AUTOMATED INSULIN DELIVERY SYSTEM MARKET – COUNTRY ANALYSIS

16.1. Latin America Automated Insulin Delivery System Market Overview by Country Segment

16.1.1. Latin America Automated Insulin Delivery System Market Volume Share By Region

16.1.2. Latin America Automated Insulin Delivery System Market Revenue Share By Region

16.2. Latin America

16.2.1. Latin America Automated Insulin Delivery System Market Volume By Country

16.2.2. Latin America Automated Insulin Delivery System Market Revenue By Country

16.2.3. Product Type

16.2.4. Latin America Automated Insulin Delivery System Market Volume By Product Type

16.2.5. Latin America Automated Insulin Delivery System Market Revenue By Product Type

16.2.6. Component

16.2.7. Latin America Automated Insulin Delivery System Market Volume By Component

16.2.8. Latin America Automated Insulin Delivery System Market Revenue By Component

16.2.9. Diabetes Type

16.2.10. Latin America Automated Insulin Delivery System Market Volume By Diabetes Type

16.2.11. Latin America Automated Insulin Delivery System Market Revenue By Diabetes Type

16.2.12. End User

16.2.13. Latin America Automated Insulin Delivery System Market Volume By End User

16.2.14. Latin America Automated Insulin Delivery System Market Revenue By End User

16.3. Brazil

16.4. Argentina

16.5. Rest of Latin America

CHAPTER NO. 17: MIDDLE EAST AUTOMATED INSULIN DELIVERY SYSTEM MARKET – COUNTRY ANALYSIS

17.1. Middle East Automated Insulin Delivery System Market Overview by Country Segment

17.1.1. Middle East Automated Insulin Delivery System Market Volume Share By Region

17.1.2. Middle East Automated Insulin Delivery System Market Revenue Share By Region

17.2. Middle East

17.2.1. Middle East Automated Insulin Delivery System Market Volume By Country

17.2.2. Middle East Automated Insulin Delivery System Market Revenue By Country

17.2.3. Product Type

17.2.4. Middle East Automated Insulin Delivery System Market Volume By Product Type

17.2.5. Middle East Automated Insulin Delivery System Market Revenue By Product Type

17.2.6. Component

17.2.7. Middle East Automated Insulin Delivery System Market Volume By Component

17.2.8. Middle East Automated Insulin Delivery System Market Revenue By Component

17.2.9. Diabetes Type

17.2.10. Middle East Automated Insulin Delivery System Market Volume By Diabetes Type

17.2.11. Middle East Automated Insulin Delivery System Market Revenue By Diabetes Type

17.2.12. End User

17.2.13. Middle East Automated Insulin Delivery System Market Volume By End User

17.2.14. Middle East Automated Insulin Delivery System Market Revenue By End User

17.3. GCC Countries

17.4. Israel

17.5. Turkey

17.6. Rest of Middle East

CHAPTER NO. 18: AFRICA AUTOMATED INSULIN DELIVERY SYSTEM MARKET – COUNTRY ANALYSIS

18.1. Africa Automated Insulin Delivery System Market Overview by Country Segment

18.1.1. Africa Automated Insulin Delivery System Market Volume Share By Region

18.1.2. Africa Automated Insulin Delivery System Market Revenue Share By Region

18.2. Africa

18.2.1. Africa Automated Insulin Delivery System Market Volume By Country

18.2.2. Africa Automated Insulin Delivery System Market Revenue By Country

18.2.3. Product Type

18.2.4. Africa Automated Insulin Delivery System Market Volume By Product Type

18.2.5. Africa Automated Insulin Delivery System Market Revenue By Product Type

18.2.6. Component

18.2.7. Africa Automated Insulin Delivery System Market Volume By Component

18.2.8. Africa Automated Insulin Delivery System Market Revenue By Component

18.2.9. Diabetes Type

18.2.10. Africa Automated Insulin Delivery System Market Volume By Diabetes Type

18.2.11. Africa Automated Insulin Delivery System Market Revenue By Diabetes Type

18.2.12. End User

18.2.13. Africa Automated Insulin Delivery System Market Volume By End User

18.2.14. Africa Automated Insulin Delivery System Market Revenue By End User

18.3. South Africa

18.4. Egypt

18.5. Rest of Africa

CHAPTER NO. 19: COMPANY PROFILES

19.1. McCormick & Company

19.1.1. Company Overview

19.1.2. Product Portfolio

19.1.3. Financial Overview

19.1.4. Recent Developments

19.1.5. Growth Strategy

19.1.6. SWOT Analysis

19.2. Archer Daniels Midland Company (ADM)

19.3. Givaudan

19.4. Döhler Group

19.5. Symrise AG

19.6. Kamis S.A.

19.7. Spice House

19.8. Rangson Group

19.9. Agarwal Agro International

19.10. Indesso

19.11. Allstate

19.12. Paul Hewitt

Frequently Asked Questions

What is the current size of the Automated Insulin Delivery System Market?

The market reached USD 4,403.17 million in 2024 and is projected to grow significantly, reaching USD 8,728.27 million by 2032.

What are the key segments within the Automated Insulin Delivery System Market?

The market segments include product type, component, diabetes type, end user, and region, covering hybrid systems, CGMs, type 1 diabetes, and hospitals.

What are some challenges faced by the Automated Insulin Delivery System Market?

Challenges include high device costs, limited reimbursement access, regulatory complexity, technical limitations, and slower adoption in low- and middle-income regions.

Who are the major players in the Automated Insulin Delivery System Market?

Major players include Medtronic, Tandem Diabetes Care, Insulet Corporation, Dexcom, Abbott, Roche, Ypsomed, Diabeloop, Beta Bionics, and Bigfoot Biomedical.

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Reviewed By
Gunakesh Parmar

Research Consultant

With over 15 years of dedicated experience in market research since 2009, specializes in delivering actionable insights from data.

View Profile

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$12699

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –